Evidence map›Paper›PMID 38750635›Full record

ArticleBioconjugate chemistry2024

High-Affinity NIR-Fluorescent Inhibitors for Tumor Imaging via Carbonic Anhydrase IX.

Gediminas Žvinys, Agne Petrosiute, Audrius Zakšauskas, Asta Zubrienė, Alvilė Ščerbavičienė, Zane Kalnina, Edita Čapkauskaitė, Vaida Juozapaitienė, Aurelija Mickevičiu Tė, Kirill Shubin and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioconjugate chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gediminas ŽvinysDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Agne PetrosiuteDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Audrius ZakšauskasDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Asta ZubrienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Alvilė ŠčerbavičienėDepartment of Biological Models, Institute of Biochemistry, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Zane KalninaLatvian Biomedical Research and Study Centre, Ratsupites 1 k-1, Riga LV-1067, Latvia.
Edita ČapkauskaitėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Vaida JuozapaitienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Aurelija Mickevičiu TėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Kirill ShubinLatvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV-1006, Latvia.
Švitrigailė GrincevičienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Steponas RaišysInstitute of Photonics and Nanotechnology, National Center for Physical Sciences and Technology, Vilnius University, Saulėtekio 3, Vilnius LT-10257, Lithuania.ORCID 0000-0002-5810-7199
Kaspars TarsLatvian Biomedical Research and Study Centre, Ratsupites 1 k-1, Riga LV-1067, Latvia.ORCID 0000-0001-8421-9023
Jurgita MatulienėDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.
Daumantas MatulisDepartment of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Saulėtekio 7, Vilnius LT-10257, Lithuania.ORCID 0000-0002-6178-6276

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor imaging and delivery of therapeutic agents may be achieved by designing high-affinity and high-selectivity compounds recognizing a tumor cell-expressing biomarker, such as carbonic anhydrase IX (CA IX). The CAIX, overexpressed in many hypoxic solid tumors, helps adjust to the energy requirements of the hypoxic environment, reduces intracellular acidification, and participates in the metastatic invasion of adjacent tissues. Here, we designed a series of sulfonamide compounds bearing CAIX-recognizing, high-affinity, and high-selectivity groups conjugated via a PEG linker to near-infrared (NIR) fluorescent probes used in the clinic for optically guided cancer surgery. We determined compound affinities for CAIX and other 11 catalytically active CA isozymes by the thermal shift assay and showed that the affinity

Indexed as

Antigens, NeoplasmCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXFluorescent DyesAnimalsCarbonic AnhydrasesHeLa CellsHumansInfrared RaysMiceMice, NudeNeoplasmsOptical ImagingSulfonamidesAntigens, NeoplasmCA9 protein, humanCarbonic Anhydrase InhibitorsCarbonic Anhydrase IXCarbonic AnhydrasesFluorescent DyesSulfonamides

Identifiers

PMID38750635
PMCPMC11191402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.